Patent intelligence · US
US 11331383
Attenuated african swine fever virus vaccine
Attenuated african swine fever virus vaccine
Patent details — US 11331383
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 17, 2022
- Expiration
- May 12, 2042
- Applicant
- The Pirbright Institute
- Claims
- 16
- CPC classes
- A61K, A61K2039/5254, A61K2039/543, A61K2039/552
Quick answer
US 11331383 (Attenuated african swine fever virus vaccine) is held by The Pirbright Institute. Status: granted. Granted May 17, 2022. Expires May 12, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- The Pirbright Institute
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K2039/5254, A61K2039/543, A61K2039/552, A61K39/12, A61P
More from The Pirbright Institute
Related pharmaceutical patents in our USPTO index.
-
US 12383631
Immune antigen specific IL-18 immunocytokines and uses thereof
granted -
US 12350120
Gum-protecting and teeth-whitening strip and preparation method thereof
granted -
US 12220447
Proteolytic enzyme composition
granted -
US 12215133
GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use
granted -
US 12173062
Modified TNF-α antibodies and uses thereof
granted -
US 12115136
Fortified CBD oil for treatment of PTSD
granted -
US 12097230
Method and composition for treating post operative conditions
granted -
US 11925686
Materials for phototherapies of ophthalmic diseases
granted
Frequently asked questions
What is US patent 11331383?
US 11331383 (Attenuated african swine fever virus vaccine) is held by The Pirbright Institute. Status: granted. Granted May 17, 2022. Expires May 12, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11331383?
The Pirbright Institute is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 57 pharmaceutical patents for this assignee.
When does US 11331383 expire?
Our index shows an expiration date of May 12, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.